Member Info for inanaco

Yes i agree she has tested 7 Konar and lindy has said the other 30 are looking Good .... apologies i took the looking good bit as a done deal

all 37 found so far out of 100's are having anti tumour effect.

Cannot see the MM, is anyone else having issues ?

agree the land lock is complete ......... Great news for Scancell not so great for mutant self cells ...

You have only been a Member Since: Wed, 14th Feb 2018 toshwings how do you know of the �6 a share posts ? how can you post with such conviction that i made them ? let me see now, you keep posting with detail that indicates your reincarnated ... the only poster that behaves in an identical ,manor that he is never wrong is Tosh ... every debate he declares himself the winner ..

well i was spot on ... toshwings is tosh a banned poster

wow! the Tosh language gets louder and louder ... get ready ... Of to the Pub ... foot stamp .... i am always right muttering under his breath

Its not a short term business toshwings ... Pre-clinical often takes 3 to 5 years ... trials can take another 7 .... so you have to predict over quite long time scales ... but this is not about short term sp movements but actual inflection points that can generate a sp of �6 a share on completion of trials, but that time scale is scancells ... you really need to understand the Biio sector before you post. scancell does not plan the trials on speculation and guess work ... like wise the market is not speculation and guess work .... your just guessing that i am wrong because you don't have a clue. prove the science wrong then you prove me wrong ... best of luck with that one

Problem is you then become like Remain MP's You want all the details before the deal ... giving the deal maker on the other side all the information that would induce a possible bad deal .... you have then set a price ... if not achieved you will be slaughtered if achieved it could then be argued it was to low silence is far better

better to use Compelled .... Driven ....

what ever ... leave you with the noise the well being your feeling is ringing only in your head

LOL ... well the difference, they have not gone out to prove the science by using third party observations I have ... what you cannot do is refute my posts .. which would damage my risk analysis however you can try if you wish ... go on be brave

http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/26.09.16-new-frontiers-in-t-cell-activation-and-targeting.pdf bed time reading ...

Comparative valuation Inovio Pharmaceuticals (INO.OQ) is a company that competes in the same field as Scancell, making it a good comparator for valuation purposes. Although Inovio also manufactures its own electroporation technology, it only has one proprietary vaccine platform (SynCon) on which there is little clinical data in cancer patients available. This contrasts with Scancell, which has two proprietary immunotherapy platforms. Despite this, Inovio is trading on an EV which 13.1x greater than the EV of Scancell. On page 46, we provide a table showing the comparative data for a group of relevant quoted peer companies. This suggests that there is considerable upside potential for Scancell.

exactly what tosh does, calls a win .... even thou he won a Hot pants suit for the AGM

You can argue with the Hardman report Commercial opportunity Scancell is operating in a very competitive environment. However, despite all the research and commercialisation of new drugs, there is still a desperate need for new effective cancer drugs associated with low toxicity. Therefore, the fact that Scancell has two novel complimentary and proprietary platforms indicates that the company is well positioned in this complex field. Based on ex-factory sales of 110 branded cancer drugs, Hardman & Co estimates that underlying growth in the global oncology market was +8-9% in 2015, worth $104.5bn. Over the last 10 years, the global oncology market showed +9.0% CAGR. Over this period, the market was driven by sales of immunotherapy drugs led by the antibodies, which represented an estimated 27% of the market in 2015. Given the scale of current development programmes, Hardman & Co expects the historic growth rate of +8-9% compound to be maintained for the foreseeable future and is forecasting that the oncology market will grow to $154-161bn in 2020. With its two differentiated platforms that can be applied to many types of cancer, Scancell�s products will become part of the overall immunotherapy segment of the market which is clearly a multi-billion dollar opportunity.

yes and Space time was erhhhh rubbish to .... re-post the thread ... if you cannot .. then you have no evidence of what reasoning i gave so you post noise .... get over yourself ..

with reasoning theoretical fabric space time ... Enstein proven by two colliding black holes causing a ripple in space time now can be detected Hicks Boson ... proven by Cern the list goes on and on .... but it takes time and timing ... and that is not part of my job. that is Scancells job. so Predictions may change due to timing ... but hey fundamentals behind it ie the science are still in play Tick Tock

its a prediction, so don't get carried away with yourself .... you cannot undermine it, as you have clearly not read the thread ... or re-posted the thread. you also have not looked at the melanoma market .. i suggest you read the hardman report ... give you some sort of idea what just SCib1 is worth and it market potential ... unless your post contains specific reasoning .. i won't bother to reply, no offence chap but your not posting of sufficient quality to get me interested ... any idiot can post noise ...

i want one